By Jonathan Gardner
Published September 29, 2026
In a high-stakes move to regain its competitive footing in the rapidly evolving weight-loss market, Danish pharmaceutical giant Novo Nordisk has announced a new licensing agreement aimed at bolstering its pipeline of next-generation obesity therapies. The deal, which targets the promising experimental candidate HRS-1596, provides the company with a potent new challenger to Eli Lilly’s market-leading Zepbound.
This latest acquisition underscores a broader, aggressive strategy by Novo Nordisk to move beyond its flagship GLP-1 blockbuster, Wegovy, as it seeks to address investor concerns regarding long-term market sustainability and the rising tide of competition from both established peers and emerging biotech players.
Main Facts: The Race for the Next Breakthrough
The core of the recent agreement involves HRS-1596, an oral medication currently designated as “Phase 1 ready.” Unlike the current wave of injectable GLP-1 agonists, HRS-1596 is being developed as an oral drug that researchers believe could offer a less burdensome dosing schedule.
Structurally, the drug functions similarly to Lilly’s Zepbound, targeting both GLP-1 and the GIP metabolic hormone. By acting on these two receptors, the drug aims to mimic the dual-hormone stimulation that has proven highly effective in driving significant weight loss in clinical trials. However, Novo’s interest in HRS-1596 is specifically tied to its potential for improved tolerability and the convenience of an oral format, which analysts suggest could be the "holy grail" of the obesity treatment market.
Chronology: A Year of Transformation for Novo
The acquisition of HRS-1596 is not an isolated event; it is the latest chapter in a turbulent and transformative period for the Danish drugmaker. Following a series of supply chain constraints and increased scrutiny from investors, Novo Nordisk has undergone a top-to-bottom restructuring.
- Late 2025 – Early 2026: Novo Nordisk officially announced a transition in leadership, installing a new CEO to oversee a shift in corporate strategy.
- Mid-2026: The company initiated a massive restructuring program, which included the difficult decision to lay off thousands of employees worldwide to streamline operations and refocus resources on R&D.
- September 2026: In a flurry of activity, the company signed multiple licensing deals, including the acquisition of experimental assets from Kallyope and a collaboration with Orbis Medicines to develop macrocyclic peptide drugs capable of oral delivery.
- Late September 2026: The formalization of the deal for Hengrui’s HRS-1596, signaling a definitive move toward the next generation of metabolic medicine.
These steps represent a pivot from a company reliant on a single dominant product to a diversified, innovation-focused powerhouse.
Supporting Data: Why Oral Delivery Matters
The current gold standard in obesity treatment, including Wegovy and Zepbound, relies on weekly injections. While highly effective, these treatments carry inherent friction for patients—specifically those who struggle with needle phobia or the inconvenience of cold-chain storage and travel logistics.
Recent clinical data from the sector suggests that the next generation of weight-loss drugs will be defined by three key metrics:
- Tolerability: Reducing the gastrointestinal side effects (nausea, vomiting) that lead to treatment discontinuation.
- Maintenance Regimens: Finding the "sweet spot" for dose frequency to ensure long-term weight management without requiring daily injections.
- Delivery Format: Transitioning from injectable to oral administration to increase patient compliance and broaden access to primary care settings.
The interest in HRS-1596 stems from the possibility that it could potentially address all three. While it remains in the earliest stages of clinical testing, its potential to provide dual-hormone efficacy in a pill form has caught the attention of market analysts and investors alike.
The Rise of Hengrui as a Global Partner
The deal also highlights the increasing influence of Chinese pharmaceutical firm Hengrui, which has quietly become one of the most sought-after partners for Western drugmakers. Since 2025, Hengrui has inked six significant licensing deals with U.S. and European firms, the highest volume of any Chinese biopharma company.
Hengrui’s technical expertise in peptide chemistry and metabolic research has made it a central node in the global obesity supply chain. Prior to the Novo deal, the company provided the backbone for the pipeline of Kailera Therapeutics, a high-profile startup that recently made waves in the capital markets.
However, the complexity of these partnerships is increasing. Leerink Partners analyst David Risinger noted that potential conflicts, such as "rights of first refusal" held by previous partners like Kailera, could complicate the development timeline for HRS-1596. Furthermore, Risinger cautioned that because the drug has yet to be tested in humans, there is "limited data available to assess its profile," meaning the deal represents a calculated risk for Novo Nordisk.
Implications: A New Era of Competition
The implications of this deal are twofold. First, it demonstrates that Novo Nordisk is no longer content to rely on its internal R&D pipeline alone; it is aggressively acquiring its way into a lead position. By securing assets from Kallyope, Orbis, and now Hengrui, Novo is essentially building a "hedged" portfolio of different metabolic technologies.
Second, the move signals that the "Obesity War" between Novo and Lilly is shifting from a battle of supply-chain logistics to a battle of molecular innovation. While Lilly currently enjoys a first-mover advantage with the dual-agonist profile of Zepbound, Novo’s rapid acquisition of oral-ready candidates suggests that the next phase of the market will be fought on the battlefield of patient convenience.
The Investor Perspective
Investors have reacted with cautious optimism. While the costs associated with these deals and the ongoing restructuring are significant, the market appears to recognize that Novo Nordisk must evolve or risk obsolescence. The path forward for HRS-1596 will be long and expensive, requiring successful navigation through the FDA’s stringent Phase 1 and 2 safety trials.
As Novo Nordisk enters the final quarter of 2026, the company finds itself at a crossroads. The success of its recent acquisitions will determine whether it can maintain its status as the leader of the metabolic health revolution or if it will be permanently overtaken by the aggressive R&D engine of Eli Lilly and the agility of the burgeoning biotech ecosystem. For now, the message from the Danish headquarters is clear: the era of the injectable blockbuster is only the beginning.
About the Author
